Uncategorized
Bausch + Lomb, Nicox announce positive phase 3 results for Vesneo
Bausch + Lomb, a subsidiary of Valeant, and Nicox announced that pivotal phase 3 studies conducted with Vesneo yielded positive top-line results, according to a joint press release.Vesneo (latanoprostene bunod; previously known as BOL-303259-X and NCX 116) is a novel nitric oxide-donating prostaglandin F2-alpha analog indicated for the reduction of IOP in patients with glaucoma or ocular hypertension.